



22nd July 2016

BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400001

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No.C/1, G Block,
Bandra Kurla Complex
Bandra (East), Mumbai 400051

Scrip Code: 500674

Scrip Code: SANOFI

Dear Sirs,

Re: Unaudited Financial Results for quarter ended 30th June 2016

We enclose herewith the Unaudited Financial Results of the Company for the quarter ended 30th June 2016 which were approved by the Board of Directors at its meeting held today.

As required by Regulation 33 (3) (c) (i) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we also enclose herewith the Limited Review Report.

Thanking you,

Yours faithfully,

SANOFI INDIA LIMITED

K.SUBRAMANI
COMPANY SECRETARY

Encl: a/a

Limited Review Report


**Review Report to
The Board of Directors
Sanofi India Limited**

1. We have reviewed the accompanying statement of unaudited financial results of Sanofi India Limited ('the Company') for the quarter and six months ended June 30, 2016 (the "Statement"). This Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S R B C & CO LLP

ICAI Firm registration number: 324982E/E300003

Chartered Accountants


per Vijay Maniar
Partner

Membership No.: 36738



Place: Mumbai

Date: July 22, 2016

SANOFI INDIA LIMITED

Registered Office : Sanofi House, C.T.S No - 117-B, L & T Business Park, Saki Vihar Road, Powai, Mumbai 400 072.

Corporate Identity Number: L24239MH1956PLC009794

Tel no: (91-22) 28032000 Fax No: (91-22) 28032846

Website: www.sanofiindia.com Email: igrc.sil@sanofi.com

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED June 30, 2016

PART I						Rs. Million
Particulars	Quarter ended 30.06.2016 Unaudited	Quarter ended 31.03.2016 Unaudited	Quarter ended 30.06.2015 Unaudited	Half Year ended 30.06.2016 Unaudited	Half Year ended 30.06.2015 Unaudited	Year ended 31.12.2015 (Audited)
1. Income from Operations						
(a) Net Sales (net of excise duty)	5,653	5,063	5,143	10,716	9,741	20,493
(b) Other Operating Income	427	381	354	808	645	1,438
Total income from Operations (net)	6,080	5,444	5,497	11,524	10,386	21,931
2 Expenditure						
(a) Cost of Materials Consumed	1,491	1,654	1,418	3,145	2,705	6,339
(b) Purchase of stock in trade	843	1,239	1,296	2,082	2,548	3,413
(c) Changes in inventories of finished goods, work in progress and stock in trade	467	(466)	(53)	1	(322)	364
(d) Employee benefits expense	858	836	789	1,694	1,576	3,333
(e) Depreciation and amortisation expense	300	301	284	601	543	1,130
(f) Other expenses	963	890	833	1,853	1,836	3,891
Total Expenses	4,922	4,454	4,567	9,376	8,886	18,470
3 Profit from Operations before other income , finance costs and exceptional items (1-2)	1,158	990	930	2,148	1,500	3,461
4 Other Income	164	256	99	420	293	514
5 Profit before finance costs and exceptional items (3+4)	1,322	1,246	1,029	2,568	1,793	3,975
6 Finance costs	7	1	1	8	2	4
7 Profit before tax and exceptional items (5-6)	1,315	1,245	1,028	2,560	1,791	3,971
8 Tax expense	462	439	386	901	665	1,594
9 Net Profit for the period before exceptional items (7-8)	853	806	642	1,659	1,126	2,377
10 Exceptional item (net of tax)	-	-	-	-	161	838
11 Net Profit for the period after exceptional items (9+10)	853	806	642	1,659	1,287	3,215
12 Paid-up equity share capital (Face Value of Rs. 10 per share)	230	230	230	230	230	230
13 Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	-	16,004
14 Earnings Per Share (EPS) before exceptional items (Rs.) (Basic and diluted EPS for the period, for the year to date and for the previous year)	37.09	35.04	27.86	72.13	48.90	103.18
15 Earnings Per Share (EPS) after exceptional items (Rs.) (Basic and diluted EPS for the period, for the year to date and for the previous year)	37.09	35.04	27.86	72.13	55.90	139.59

PART II						
Particulars						
A. PARTICULARS OF SHAREHOLDING						
1 Public Shareholding						
- Number of Shares	9,121,035	9,121,035	9,121,035	9,121,035	9,121,035	9,121,035
- Percentage of Shareholding	39.60%	39.60%	39.60%	39.60%	39.60%	39.60%
2 Promoters and Promoter group Shareholding						
a) Pledged/Encumbered						
- Number of shares	NIL	NIL	NIL	NIL	NIL	NIL
- Percentage of shares (as a % of total shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL	NIL	NIL
- Percentage of shares (as a % of total share capital of the company)	NIL	NIL	NIL	NIL	NIL	NIL
b) Non-encumbered						
- Number of shares	13,909,587	13,909,587	13,909,587	13,909,587	13,909,587	13,909,587
- Percentage of shares (as a % of total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
- Percentage of shares (as a % of total share capital of the company)	60.40%	60.40%	60.40%	60.40%	60.40%	60.40%

Particulars	3 Months ended June 30, 2016
B. INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	-
Received during the quarter	12
Disposed of during the quarter	12
Remaining unresolved at the end of the quarter	-




in mio

Particulars	As at June 30, 2016 Unaudited	As at Dec 31, 2015 Audited
EQUITY AND LIABILITIES :		
Shareholders' funds :		
(a) Share capital	230	230
(b) Reserves & Surplus *	17,200	16,041
Sub-total - Shareholder's Funds	17,430	16,271
Non-current liabilities		
(a) Other long term liabilities	114	114
(b) Long term provisions	280	288
(c) Deferred Tax Liabilities (Net)	1,150	1,203
Sub-total - Non-current liabilities	1,544	1,605
Current liabilities		
(a) Trade Payables	2,193	2,256
(b) Other current liabilities	838	1,061
(c) Short-term provisions	2,312	2,853
Sub-total - Current liabilities	5,343	6,170
TOTAL EQUITY & LIABILITIES	24,317	24,046
ASSETS		
Non-current assets		
(a) Fixed Assets (Including Capital Work in Progress)	8,717	8,992
(b) Non current investments	2	2
(c) Long term loans and advances	2,874	2,598
(d) Other non-current assets	17	17
Sub-total - Non-current assets	11,610	11,609
Current assets		
(a) Inventories	4,490	4,792
(b) Trade receivables	1,632	1,441
(c) Cash & Bank Balances	5,962	5,715
(d) Short term loans & advances	601	437
(e) Other current assets	22	52
Sub-total - Current assets	12,707	12,437
TOTAL ASSETS	24,317	24,046

* After considering Interim Dividend






Notes:

1. The above Results were approved by the Board of Directors of the Company at its Meeting held on July 22, 2016.
2. In accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company's Statutory Auditors have conducted a 'Limited Review' of the Financial Results for the quarter ended June 30, 2016.
3. The Board of Directors has declared an Interim Dividend of Rs.18 per Equity share of Rs 10 to be paid to those Members whose names appear on the Register of Members of the Company on August 5, 2016 being the Record Date. The said dividend will be paid on August 16, 2016.
4. The Company has a single business segment namely 'Pharmaceutical Business'.
5. The figures for the previous periods have been re-grouped, wherever necessary.



SANOFI INDIA LIMITED

SHAILESH AYYANGAR

MANAGING DIRECTOR

July 22, 2016

↓
LG